Observational study of XELOX in combination with bevacizumab for advanced or recurrent colorectal cancer

ABSTRACT: Interventions: Oxaliplatin 130mg/m2 i.v.(day1) Bevacizumab 7.5mg/kg i.v.(day1) Capecitabine 2000mg/m2 p.o.(day1-14) to be repeated every 3weeks Primary outcome(s): Overall response rate Study Design: Single arm Non-randomized

DISEASE(S): Advanced And Recurrent Colorectal Cancer

PROVIDER: 2620414 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR